Surge in Multiple Sclerosis Treatment Sales Leads to Significant 2026 Performance Guidance Upgrade

TG Therapeutics, Inc. (NASDAQ: TGTX) reported first-quarter 2026 revenues of approximately $205 million. U.S. sales of its lead multiple sclerosis therapy, BRIUMVI®, reached about $194.8 million, marking a roughly 63% year-over-year increase. The company recorded net income of $19.8 million and raised its 2026 global revenue guidance to about $925 million, as well as its U.S. BRIUMVI sales guidance to $885 million–$900 million. Concurrently, TG Therapeutics secured approximately $500 million in non-dilutive financing from Blue Owl Capital and expanded its share repurchase authorization to $300 million, having repurchased $200 million of its stock since 2024.

In its full-year 2025 earnings release, TG Therapeutics also upgraded its 2026 revenue outlook on the back of strong BRIUMVI sales—a revised forecast that external analysts have reiterated, underscoring a growth strategy focused on BRIUMVI. The recent publication of clinical data on a simplified BRIUMVI regimen and the announcement of additional clinical milestones expected around 2026 have further attracted market attention to the company’s plan to broaden its multiple sclerosis portfolio.

TG Therapeutics, a Nasdaq-listed biotechnology company, concentrates on developing and commercializing central nervous system autoimmune disease therapies, with its relapsing multiple sclerosis treatment BRIUMVI at the forefront. As major pharmaceutical players compete in the multiple sclerosis market, demand is rising for antibody- and cell-based therapies, making novel mechanisms of action and dosing convenience key competitive differentiators.